New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
11:04 EDTIMMUImmunomedics reports results from three IMMU-130 phase I trials
Immunomedics reported the results from 3 Phase I trials with IMMU-130, the company's investigational anti-CEACAM5 antibody conjugated to the irinotecan-metabolite, SN-38. The antibody-drug conjugate was therapeutically active in all 3 trials, but a more frequent dosing schedule, with administrations of IMMU-130 once or twice-weekly for 2 weeks followed by a week off, was more active in patients with metastatic colorectal cancer than when administered every other week. Results from these Phase I studies were presented at the 2014 Annual Meeting of the American Association for Cancer Research in San Diego, CA, by a group of clinical investigators. In all three trials, measurement of SN-38 concentrations in the serum found much higher levels that were sustained longer than is typically found with irinotecan therapy, the parental drug of SN-38. However, most of the SN-38 remains bound to the antibody, keeping it in an inactive form to normal tissues while in circulation, which reduces toxicity, yet allowing for higher concentrations of activated SN-38 to be delivered to the tumor where it is released from the pH- sensitive linker. Neutropenia and manageable diarrhea were the main side effects. "These results suggest that IMMU-130 may have a high therapeutic index and can be administered in repeated cycles in advanced mCRC patients," commented CEO Cynthia Sullivan.
News For IMMU From The Last 14 Days
Check below for free stories on IMMU the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
06:15 EDTIMMUImmunomedics files $130M mixed securities shelf
Subscribe for More Information
September 12, 2014
12:20 EDTIMMUImmunomedics management to meet with Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use